Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of Mycophenolate mofetil in Korea

Transplantation Proceedings

Volumn 42, Issue 3, 2010, Pages 793-796

  Lee, S ^a,b   Shin, M ^a   Kim, E ^a   Kim, J M ^a   Moon, J ^a   Jung, G ^a   Choi, G ^a   Kwon, C ^a   Joh, J ^a   Kim, S ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Jinju Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BLOOD; CADAVER; DONOR; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; OPPORTUNISTIC INFECTION; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; TIME;

ADULT; CADAVER; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MYCOPHENOLIC ACID; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TISSUE DONORS;

EID: 77955475289     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.02.061     Document Type: Conference Paper

References (23)

1. P. Liptak, and B. Ivanyi Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Nat Clin Pract Nephrol 2 2006 398
2. B.J. Nankivell, R.J. Borrows, and C.L. Fung Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology Transplantation 78 2004 557
3. S.M. Flechner, D. Goldfarb, and C. Modlin Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine Transplantation 74 2002 1070
4. B. Suwelack, U. Gerhardt, and H. Hohage Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy Am J Transplant 4 2004 655
5. H.W. Sollinger Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients U.S. Renal Transplant Mycophenolate Mofetil Study Group Transplantation 60 1995 225
6. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 345 1995 1321
7. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61 1996 1029
8. T. van Gelder, and L.M. Shaw The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation Transplantation 80 2005 S244
9. M. Naesens, H. de Loor, and Y. Vanrenterghem The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-0 O-glucuronide Transplantation 84 2007 362
10. L.T. Weber, M. Shipkova, and T. Lamersdorf Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients J Am Soc Nephrol 9 1998 1511
11. L.M. Shaw, M. Korecka, and S. Aradhye Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable J Clin Pharmacol 40 2000 624
12. F.M. Gonzalez-Roncero, M.A. Gentil, and M. Brunet Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency Transplant Proc 37 2005 3749
13. B. Kaplan, H.U. Meier-Kriesche, and G. Friedman The effect of renal insufficiency on mycophenolic acid protein binding J Clin Pharmacol 39 1999 715
14. D. Cattaneo, N. Perico, and F. Gaspari Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation Kidney Int 62 2002 1060
15. D.A. Hesselink, R.M. van Hest, and R.A. Mathot Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 Am J Transplant 5 2005 987
16. R. Engelbertink, P. Smak Gregoor, and C. Hesse High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment Transplant Proc 34 2002 2983
17. M. Kobayashi, H. Saitoh, and K. Tadano Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats J Pharmacol Exp Ther 309 2004 1029
18. R.S. Gaston, B. Kaplan, and T. Shah Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial Am J Transplant 9 2009 1607
19. T. van Gelder Mycophenolate blood level monitoring: recent progress Am J Transplant 9 2009 1495
20. T. van Gelder, H.T. Silva, and J.W. de Fijter Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial Transplantation 86 2008 1043
21. Y. Le Meur, M. Buchler, and A. Thierry Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation Am J Transplant 7 2007 2496
22. D.R. Kuypers, K. Claes, and P. Evenepoel Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients J Clin Pharmacol 43 2003 866
23. C. Le Guellec, M. Buchler, and B. Giraudeau Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy Eur J Clin Pharmacol 57 2002 805